Ítem
Solo Metadatos

Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

dc.creatorArevalo, J. Fernandospa
dc.creatorSanchez, Juan G.spa
dc.creatorFromow-Guerra, Jansspa
dc.creatorWu, Lihtehspa
dc.creatorBerrocal, Maria H.spa
dc.creatorFarah, Michel E.spa
dc.creatorCardillo, Josespa
dc.creatorRodríguez, Francisco J.spa
dc.creatorfor the Pan-American Collaborative Retina Study Group (PACORES)spa
dc.creator.OrganizationalPan-American Collaborative Retina Study Group (PACORES)
dc.date.accessioned2020-05-26T00:09:42Z
dc.date.available2020-05-26T00:09:42Z
dc.date.created2009spa
dc.description.abstractBackground: To report the 12-month anatomic and ETDRS best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin®) (1.25 mg or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In addition, a comparison of the two different doses of intravitreal bevacizumab (IVB) utilized was made. Methods: We reviewed the clinical records of 82 consecutive patients (101 eyes) with DDME in this interventional retrospective multicenter study. All patients with a minimum follow-up of 12 months (mean 57.6±8.4 weeks) were included in this analysis. Patients underwent ETDRS best-corrected visual acuity (BCVA) testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Results: The mean age of our patients was 59.7±9.3 years. The mean number of IVB injections per eye was three (range: one to six injections) at a mean interval of 14.1±10.5 weeks. In the 1.25 mg group at 1 month BCVA improved from 20/190, logMAR=0.97 to 20/85, logMAR 0.62, a difference that was statistically significant (p=0.0001). This improvement was maintained throughout the 3-, 6-, and 12-month follow-up. The mean final BCVA at 12 months was 20/76, logMAR=0.58 (p less than 0.001), a statistically significant difference from baseline BCVA. Similar BCVA changes were observed in the 2.5 mg group. In the 1.25 mg group, the mean central macular thickness (CMT) decreased from 419.1±201.1 ?m at baseline to 295.11±91.5 ?m at 1 month, 302.1±124.2 m at 5 months, 313.4.1±96.3 m at 6 months, and 268.2±95.5 m at 12 months (plt;0.0001). Similar CMT changes were observed in the 2.5 mg group. Adverse events included transient high blood pressure in one patient (1.2%), transient increased intraocular pressure in one eye (1%), and tractional retinal detachment in one eye (1%). Conclusions: Primary IVB at doses of 1.25 to 2.5 mg seem to provide stability or improvement in BCVA, OCT, and FA in DDME at 12 months. There seems to be no difference in our results between intravitreal bevacizumab at doses of 1.25 mg or 2.5 mg. In addition, our results suggest the need for at least three injections a year to maintain the BCVA results. © Springer-Verlag 2009.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1007/s00417-008-1034-x
dc.identifier.issn0721832X
dc.identifier.issn1435702X
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/24173
dc.language.isoengspa
dc.relation.citationEndPage743
dc.relation.citationIssueNo. 6
dc.relation.citationStartPage735
dc.relation.citationTitleGraefe`s Archive for Clinical and Experimental Ophthalmology
dc.relation.citationVolumeVol. 247
dc.relation.ispartofGraefe's Archive for Clinical and Experimental Ophthalmology, ISSN:0721832X, 1435702X, Vol.247, No.6 (2009); pp. 735-743spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-67349157689&doi=10.1007%2fs00417-008-1034-x&partnerID=40&md5=8c14da8e77ba55bd294706db037a8be6spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordBevacizumabspa
dc.subject.keywordoptical coherenceeng
dc.subject.keywordArticlespa
dc.subject.keywordCerebrovascular accidentspa
dc.subject.keywordClinical trialspa
dc.subject.keywordComparative studyspa
dc.subject.keywordControlled clinical trialspa
dc.subject.keywordControlled studyspa
dc.subject.keywordCornea thicknessspa
dc.subject.keywordDiabetic macular edemaspa
dc.subject.keywordDose responsespa
dc.subject.keywordDrug dose comparisonspa
dc.subject.keywordDrug efficacyspa
dc.subject.keywordDrug safetyspa
dc.subject.keywordDrug stabilityspa
dc.subject.keywordFemalespa
dc.subject.keywordFluorescence angiographyspa
dc.subject.keywordFollow upspa
dc.subject.keywordHeart infarctionspa
dc.subject.keywordHumanspa
dc.subject.keywordHypertensionspa
dc.subject.keywordIntraocular pressurespa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordMalespa
dc.subject.keywordMulticenter studyspa
dc.subject.keywordOff label drug usespa
dc.subject.keywordOphthalmoscopyspa
dc.subject.keywordOptical coherence tomographyspa
dc.subject.keywordPeripheral vascular diseasespa
dc.subject.keywordPriority journalspa
dc.subject.keywordRetina detachmentspa
dc.subject.keywordSide effectspa
dc.subject.keywordThromboembolismspa
dc.subject.keywordTransient ischemic attackspa
dc.subject.keywordVisual acuityspa
dc.subject.keywordAngiogenesis inhibitorsspa
dc.subject.keywordAntibodieseng
dc.subject.keywordCooperative behaviorspa
dc.subject.keywordDiabetic retinopathyspa
dc.subject.keywordFemalespa
dc.subject.keywordFluorescein angiographyspa
dc.subject.keywordFollow-up studiesspa
dc.subject.keywordHumansspa
dc.subject.keywordInjectionsspa
dc.subject.keywordMacular edemaspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle agedspa
dc.subject.keywordRetinaspa
dc.subject.keywordRetreatmentspa
dc.subject.keywordRetrospective studiesspa
dc.subject.keywordTomographyeng
dc.subject.keywordTreatment outcomespa
dc.subject.keywordVascular endothelial growth factor aspa
dc.subject.keywordVisual acuityspa
dc.subject.keywordVitreous bodyspa
dc.subject.keywordAvastinspa
dc.subject.keywordBevacizumabspa
dc.subject.keywordDiffuse diabetic macular edemaspa
dc.subject.keywordIntravitreal injectionsspa
dc.subject.keywordOctspa
dc.subject.keywordPrimary treatmentspa
dc.titleComparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-upspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones